Based on 5 Wall Street analysts offering 12 month price targets for Wuxi Biologics (Cayman) in the last 3 months. The average price target is $3.28 with a high forecast of $4.50 and a low forecast of $2.57. The average price target represents a 42.61% change from the last price of $2.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.4955078,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5688616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.27,2.4411929076923076,2.6123858153846156,2.783578723076923,2.9547716307692307,3.1259645384615387,3.297157446153846,3.468350353846154,3.6395432615384617,3.8107361692307693,3.9819290769230773,4.153121984615385,4.324314892307692,{"y":4.4955078,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.27,2.3476923076923075,2.4253846153846155,2.503076923076923,2.5807692307692305,2.6584615384615384,2.736153846153846,2.8138461538461534,2.8915384615384614,2.9692307692307693,3.046923076923077,3.1246153846153844,3.2023076923076923,{"y":3.28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.27,2.2929893538461537,2.3159787076923077,2.3389680615384614,2.3619574153846155,2.384946769230769,2.407936123076923,2.430925476923077,2.453914830769231,2.4769041846153845,2.4998935384615386,2.5228828923076922,2.545872246153846,{"y":2.5688616,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.66,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$4.50

Average Price Target$3.28

Lowest Price Target$2.57

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

CMB International Securities

xxxxxxxxxxxxx

Reiterated

01/17/25

Reiterated

01/13/25

Upgraded

01/08/25

Reiterated

12/06/24

Reiterated

10/25/24

xxxxxxxxxxxxx

Sean Wu CFA

Morgan Stanley

$4.11

Buy

78.70%

Upside

Reiterated

08/30/24

Morgan Stanley Reiterates Overweight Rating on Wuxi Biologics (2269:HK) (WXXWY)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$32.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Jialin Zhang

Nomura

$2.99→$2.48

Buy

7.78%

Upside

Reiterated

08/22/24

Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$19.30 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang lowered the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$19.30 (from HK$23.25) while maintaining a Buy rating.

Chen Chen

UBS

$2.13

Hold

-7.30%

Downside

Reiterated

06/12/24

UBS Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)UBS analyst Chen Chen reiterated a Neutral rating and HK$16.60 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Ziyi Chen

Goldman Sachs

$2.77→$2.49

Hold

8.34%

Upside

Reiterated

04/11/24

Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$19.40 at Goldman SachsGoldman Sachs analyst Ziyi Chen lowered the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$19.40 (from HK$21.60) while maintaining a Neutral rating.

Tony Ren

Macquarie

$4.88→$1.8

Hold

-21.82%

Downside

Reiterated

03/28/24

Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$14 at MacquarieMacquarie analyst Tony Ren lowered the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$14.00 (from HK$38.00) while maintaining a Neutral rating.

Nithya Balasubramanian

Bernstein

$6.68

Buy

190.39%

Upside

Reiterated

02/13/24

Wuxi Biologics: Navigating the Biosecure Act with Resilience and Optimism

Best Analysts Covering Wuxi Biologics (Cayman)

Which Analyst Should I Follow If I Want to Buy WXIBF and Sell After:

1 Month

xxx

Success Rate

2/4 ratings generated profit

Average Return

+1.95%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.95% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+15.02%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.02% per trade.

1 Year

Jialin ZhangNomura

Success Rate

2/4 ratings generated profit

Average Return

+13.88%

reiterated a buy rating 5 months ago

Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.88% per trade.

2 Years

xxx

Success Rate

2/4 ratings generated profit

Average Return

+17.68%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +17.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WXIBF Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Dec 24

Jan 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WXIBF has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. WXIBF average Analyst price target in the past 3 months is $3.28.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

WXIBF Financial Forecast

WXIBF Earnings Forecast

Next quarter’s earnings estimate for WXIBF is $0.06 with a range of $0.06 to $0.06. The previous quarter’s EPS was $0.05. WXIBF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.86% of the time in the same period. In the last calendar year WXIBF has Preformed in-line its overall industry.

WXIBF Sales Forecast

Next quarter’s sales forecast for WXIBF is $1.29B with a range of $1.28B to $1.30B. The previous quarter’s sales results were $1.19B. WXIBF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.55% of the time in the same period. In the last calendar year WXIBF has Outperformed its overall industry.

WXIBF Stock Forecast FAQ

What is WXIBF’s average 12-month price target, according to analysts?

Based on analyst ratings, Wuxi Biologics (Cayman) Inc.’s 12-month average price target is $3.28.

What is WXIBF’s upside potential, based on the analysts’ average price target?

Wuxi Biologics (Cayman) Inc. has 42.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WXIBF a Buy, Sell or Hold?

Wuxi Biologics (Cayman) Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wuxi Biologics (Cayman) Inc.’s price target?

The average price target for Wuxi Biologics (Cayman) Inc. is $3.28. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $4.50 ,the lowest forecast is $2.57. The average price target represents 42.61% Increase from the current price of $2.3.

What do analysts say about Wuxi Biologics (Cayman) Inc.?

Wuxi Biologics (Cayman) Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of WXIBF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wuxi Biologics (Cayman) (WXIBF) Stock Forecast & Price Target

WXIBF Analyst Ratings

WXIBF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wuxi Biologics (Cayman)

WXIBF Analyst Recommendation Trends

WXIBF Financial Forecast

WXIBF Earnings Forecast

WXIBF Sales Forecast

WXIBF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts